...
首页> 外文期刊>The Journal of Urology >Effects of estrogen, raloxifene and levormeloxifene on alpha1A-adrenergic receptor expression.
【24h】

Effects of estrogen, raloxifene and levormeloxifene on alpha1A-adrenergic receptor expression.

机译:雌激素,雷洛昔芬和左美洛昔芬对α1A-肾上腺素受体表达的影响。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: We investigated the effect of estrogen, raloxifene and levormeloxifene on alpha1A-adrenergic receptor expression. MATERIALS AND METHODS: Postpartum rats underwent intravaginal balloon injury and ovariectomy, and were then treated with estrogen or placebo for 8 weeks. The urethras were examined for alpha1A-adrenergic receptor expression by Western blot analysis and immunohistochemistry. Urethral smooth muscle cells were isolated from untreated female rats and examined for the expression of estrogen receptors alpha and beta by immunofluorescence microscopy. Urethral smooth muscle cells were treated with estrogen, raloxifene or levormeloxifene for 24 hours and examined for alpha1A-adrenergic receptor expression by real-time polymerase chain reaction. The effects of these drugs on alpha1A-adrenergic receptor expression were further examined by promoter assays. RESULTS: Estrogen treatment resulted in decreased alpha1A-adrenergic receptor expression in the urethras. Urethral smooth muscle cells expressed estrogen receptors alpha and beta, the former predominantly in the cytoplasm and the latter in the nucleus. Estrogen significantly down-regulated alpha1A-adrenergic receptor mRNA expression, while raloxifene and levormeloxifene had no significant effect. Estrogen also significantly down-regulated alpha1A-adrenergic receptor promoter in the presence of estrogen receptor alpha or beta. Raloxifene and levormeloxifene up-regulated alpha1A-adrenergic receptor promoter in the presence of estrogen receptor alpha but not beta. CONCLUSIONS: Estrogen down-regulated alpha1A-adrenergic receptor expression in the urethral smooth muscle of female rats, while raloxifene and levormeloxifene had no significant effect. These findings represent a possible molecular mechanism through which estrogen, raloxifene and levormeloxifene differentially affect urinary continence.
机译:目的:我们调查了雌激素,雷洛昔芬和左美洛昔芬对α1A-肾上腺素能受体表达的影响。材料与方法:产后大鼠进行阴道内球囊损伤和卵巢切除术,然后用雌激素或安慰剂治疗8周。通过蛋白质印迹分析和免疫组织化学检查尿道中α1A-肾上腺素能受体的表达。从未经处理的雌性大鼠中分离出尿道平滑肌细胞,并通过免疫荧光显微镜检查雌激素受体α和β的表达。尿道平滑肌细胞用雌激素,雷洛昔芬或左美洛昔芬治疗24小时,并通过实时聚合酶链反应检查α1A-肾上腺素能受体的表达。通过启动子试验进一步检查了这些药物对α1A-肾上腺素受体表达的影响。结果:雌激素治疗导致尿道中α1A-肾上腺素能受体的表达减少。尿道平滑肌细胞表达雌激素受体α和β,前者主要在细胞质中,后者在细胞核中。雌激素显着下调了α1A-肾上腺素受体mRNA的表达,而雷洛昔芬和左美洛昔芬没有明显的作用。在存在雌激素受体α或β的情况下,雌激素还显着下调α1A-肾上腺素受体启动子。在存在雌激素受体α但不存在β的情况下,雷洛昔芬和左美洛昔芬上调了α1A-肾上腺素能受体启动子。结论:雌激素下调雌性大鼠尿道平滑肌中α1A-肾上腺素能受体的表达,而雷洛昔芬和左美洛昔芬则无明显作用。这些发现代表了一种可能的分子机制,雌激素,雷洛昔芬和左美洛昔芬通过它们差异影响尿失禁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号